

66/21/99
Jc518 U.S. PTO

Jc511 U.S. PTO
09/235073
01/21/99

PATENT

Docket No. 99-1

Commissioner of Patents and Trademarks
Washington, D.C. 20231

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of

Inventor(s):

Mark de Boer
marcel theodorus

WARNING: Patent must be applied for in the name(s) of all of the actual inventor(s). 37 CFR 1.41(a) and 1.53(b).

For (title):

Induction of T Cell Tolerance with CD40/B7 Antagonists
~~Molecule that can simultaneously block two costimulatory pathways~~

1. Type of Application

This new application is for a(n) (check one applicable item below):



Original National Phase of PCT Application PC/PL 97/00438



Design



Plant

WARNING: Do not use this transmittal for a completion in the U.S. of an International Application under 35 U.S.C. 371(c)(4) unless the International Application is being filed as a divisional, continuation or continuation-in-part application.

NOTE: If one of the following 3 items apply then complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF A PRIOR U.S. APPLICATION CLAIMED.



Divisional



Continuation



Continuation-in-part (CIP)

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this New Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date _____ in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number _____ addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

(Type or print name of person mailing paper)

(Signature of person mailing paper)

NOTE: Each paper or fee referred to as enclosed herein has the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 CFR 1.10(b).

(Application Transmittal [4-1]—page 1 of 7)

60/022,070 and PCT Application PCT/NL 97/00438

2. Benefit of Prior U.S. Application(s) (35 USC 120)

NOTE: If the new application being transmitted is a divisional, continuation or a continuation-in-part of a parent case, or where the parent case is an International Application which designated the U.S., then check the following item and complete and attach **ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.**

- ☐ The new application being transmitted claims the benefit of prior U.S. application(s) and enclosed are **ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.**

3. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b) (Regular) or 37 CFR 1.153 (Design) Application

- ☐ Pages of specification
☐ Pages of claims
☐ Pages of Abstract
☐ Sheets of drawing
☐ formal
☐ Informal

WARNING: DO NOT submit original drawings. A high quality copy of the drawings should be supplied when filing a patent application. The drawings that are submitted to the Office must be on strong, white, smooth, and non-shiny paper and meet the standards according to § 1.84. If corrections to the drawings are necessary, they should be made to the original drawing and a high-quality copy of the corrected original drawing then submitted to the Office. Only one copy is required or desired. Comments on proposed new 37 CFR 1.84, Notice of March 9, 1988 (1990 O.G. 57-62).

NOTE: "Identifying indicia such as the serial number, group and unit, title of the invention, attorney's docket number, inventor's name, number of sheets, etc., not to exceed 2 1/4 inches (7.0 cm.) in width may be placed in a centered location between the side edges within three fourths inch (19.1 mm.) of the top edge. Either this marking technique on the front of the drawing or the placement, although not preferred, of this information and the title of the invention on the back of the drawings is acceptable." Proposed 37 CFR 1.84(1). Notice of March 9, 1988 (1090 O.G. 57-62).

4. Additional papers enclosed

- ☐ Preliminary Amendment
☒ Information Disclosure Statement
☐ Form PTO-1449
☐ Citations
☐ Declaration of Biological Deposit
☐ Authorization of Attorney(s) to Accept and Follow Instructions from Representative
☐ Special Comments
☐ Other

(Application Transmittal [4-1]—page 2 of 7)

5. Declaration or oath☐ Enclosed

executed by (check all applicable boxes)

☐ Inventor(s).☐ legal representative of inventor(s). 37 CFR 1.42 or 1.43☐ joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached.☐ this is the petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 is also attached. See item 13 below for fee.☐ Not Enclosed.

WARNING: Where the filing is a completion in the U.S. of an International Application but where a declaration is not available or where the completion of the U.S. application contains subject matter in addition to the International Application the application may be treated as a continuation or continuation-in-part, as the case may be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION CLAIMED.

☐ Application is made by a person authorized under 37 CFR 1.41(c) on behalf of all the above named inventor(s). The declaration or oath, along with the surcharge required by 37 CFR 1.16(e) can be filed subsequently.

Note: It is important that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b).

☐ Showing that the filing is authorized. (Not required unless called into question. 37 CFR 1.41(d).)**6. Inventorship Statement**

WARNING: If the named inventors are each not the inventors of all the claims an explanation, including the ownership of the various claims at the time the last claimed invention was made, should be submitted.

The inventorship for all the claims in this application are:

☒ The same

or

☐ Are not the same. An explanation, including the ownership of the various claims at the time the last claimed invention was made,☐ is submitted.☐ will be submitted.**7. Language**

NOTE: An application including a signed oath or declaration may be filed in a language other than English. A verified English translation of the non-English language application and the processing fee of \$30.00 required by 37 CFR 1.17(k) is required to be filed with the application or within such time as may be set by the Office. 37 CFR 1.52(d).

NOTE: A non-English oath or declaration in the form provided or approved by the PTO need not be translated. 37 CFR 1.69(b).

☒ English☐ non-English☐ the attached translation is a verified translation. 37 CFR 1.52(d).

8. Assignment

- ☒ An assignment of the invention to Tanot, Inc.
- ☐ Is attached.
- ☒ will follow.

9. Certified Copy

Certified copy(ies) of application(s)

(country)	(appln. no.)	(filed)
(country)	(appln. no.)	(filed)
(country)	(appln. no.)	(filed)

from which priority is claimed

- ☐ Is(are) attached.
- ☒ will follow.

Note: The foreign application forming the basis for the claim for priority must be referred to in the oath or declaration. 37 CFR 1.55(a) and 1.63.

NOTE: This item is for any foreign priority for which the application being filed directly relates. If any parent U.S. application or International Application from which this application claims benefit under 35 U.S.C. 120 is itself entitled to priority from a prior foreign application then complete item 18 on the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

10. Fee Calculation (37 CFR 1.16)

A. ☒ Regular application

CLAIMS AS FILED			
Number filed	Number Extra	Rate	Basic Fee
			\$370.00 530.00
Total Claims	— 20 =	X	\$ 12.00
Independent Claims (37 CFR 1.16(b))	— 3 =	X	\$ 36.00
Multiple dependent claim(s), if any (37 CFR 1.16(d))			\$120.00

- ☐ Amendment cancelling extra claims enclosed.
- ☐ Amendment deleting multiple dependencies enclosed.
- ☐ Fee for extra claims is not being paid at this time.

NOTE: If the fees for extra claims are not paid on filing they must be paid or the claims cancelled by amendment, prior to the expiration of the time period set for response by the Patent and Trademark Office in any notice of fee deficiency. 37 CFR 1.16(d).

Filing Fee Calculation

\$ 530.00

(Application Transmittal [4-1]—page 4 of 7)

- B. ☐ Design application
(\$150.00—37 CFR 1.16(f))

Filing Fee Calculation

\$ _____

- C. ☐ Plant application
(\$250.00—37 CFR 1.16(g))

Filing fee calculation

\$ _____

11. Small Entity Statement(s)

- ☒ Verified Statement(s) that this is a filing by a small entity under 37 CFR 1.9 and 1.27 is(are) attached.

Filing Fee Calculation (50% of A, B or C above)

\$ 530.00

NOTE: Any excess of the full fee paid will be refunded if a verified statement and a refund request are filed within 2 months of the date of timely payment of a full fee. 37 CFR 1.28(a).

12. Request for International-Type Search (37 CFR 1.104(d)) (complete, if applicable)

- ☐ Please prepare an international-type search report for this application at the time when national examination on the merits takes place.

13. Fee Payment Being Made At This Time

- ☐ Not Enclosed

- ☐ No filing fee is to be paid at this time. (This and the surcharge required by 37 CFR 1.16(e) can be paid subsequently.)

- ☒ Enclosed

- ☒ basic filing fee \$ _____

- ☐ recording assignment (\$8.00; 37 CFR 1.21(h)) \$ _____

- ☐ petition fee for filing by other than all the inventors or person on behalf of the inventor where inventor refused to sign or cannot be reached. (\$120.00; 37 CFR 1.47 and 1.17(h)) \$ _____

- ☐ for processing an application with a specification in a non-English language. (\$30.00; 37 CFR 1.52(d) and 1.17(k)) \$ _____

- ☐ processing and retention fee (\$120.00; 37 CFR 1.53(d) and 1.21(l)) \$ _____

- ☐ fee for international-type search report (\$30.00; 37 CFR 1.21(e)). \$ _____

NOTE: 37 CFR 1.21(l) establishes a fee for processing and retaining any application which is abandoned for failing to complete the application pursuant to 37 CFR 1.53(d) and this, as well as the changes to 37 CFR 1.53 and 1.78, indicate that in order to obtain the benefit of a prior U.S. application, either the basic filing fee must be paid or the processing and retention fee of § 1.21(l) must be paid within 1 year from notification under § 53(d).

Total fees enclosed

\$ 530.00

(Application Transmittal [4-1]—page 5 of 7)

14. Method of Payment of Fees

- ☒ Check in the amount of \$ 530.00
- ☐ Charge Account No. _____ in the amount of \$ _____. A duplicate of this transmittal is attached.

NOTE: Fees should be itemized in such a manner that it is clear for which purpose the fees are paid. 37 CFR 1.22(b).

15. Authorization to Charge Additional Fees

WARNING: If no fees are to be paid on filing the following items should not be completed.

WARNING: Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges, if extra claim charges are authorized.

- ☒ The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 20-0087:

- ☒ 37 CFR 1.16(a), (f) or (g) (filing fees)
- ☒ 37 CFR 1.16(b), (c) and (d) (presentation of extra claims)

NOTE: Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 CFR 1.16(d)), it might be best not to authorize the PTO to charge additional claim fees, except possibly when dealing with amendments after final action.

- ☒ 37 CFR 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)
- ☒ 37 CFR 1.17 (application processing fees)

WARNING: While 37 CFR 1.17(a), (b), (c) and (d) deal with extensions of time under § 1.136(a) this authorization should be made only with the knowledge that: "Submission of the appropriate extension fee under 37 C.F.R. 1.136(a) is to no avail unless a request or petition for extension is filed." (Emphasis added). Notice of November 5, 1985 (1060 O.G. 27).

- ☒ 37 CFR 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 CFR 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 CFR 1.311(b).


NOTE: 37 CFR 1.28(b) requires "Notification of any change in loss of entitlement to small entity status must be filed in the application . . . prior to paying, or at the time of paying, . . . issue fee". From the wording of 37 CFR 1.28(b): (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

16. Instructions As To Overpayment

- ☒ credit Account No. 20-0087
- ☐ refund

Reg. No. 31,211

Tel. No. (713) 664-2288



SIGNATURE OF ATTORNEY

ERIC MIRABEL

Type or print name of attorney

Tanox, 10301 Stella Link

P.O. Address

Houston TX 77025

(Application Transmittal [4-1]—page 6 of 7)

PATENT

Attorney's Docket No. 99-1

Serial or Patent No.:

File or Issued: herewith

For: **Induction of T Cell Tolerance with CD40/B7 Antagonists**

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am an official of the small business concern empowered to act on behalf of the concern identified as Tanox, Inc., 10301 Stella Link, Houston, Texas 77025.

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third-party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed, to and remain with the small business concern identified above with regard to the invention, entitled

Induction of T Cell Tolerance with CD40/B7 Antagonists

BY:


Mark de Boer and Marcel Theodorus, described in the specification filed herewith.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).


I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the

earliest of the issue fee or any maintenance fee due after the date on which status as a small business entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.



John Morris,
Senior Vice President of Operations,
Tanox, Inc.
10301 Stella Link
Houston Texas 77025



Date

31\frm\small.doc

INDUCTION OF T CELL TOLERANCE WITH CD40/B7 ANTAGONISTS

Field of the Invention

This invention relates to methods of treating diseases with CD40/B7 antagonists.

Background of the invention

Activation of T cells:

Activation of T cells is known to require multiple interactions with antigen presenting cells ("APC"). The TcR-CD3 complex has two functions in antigen-induced activation: a recognition function in which a specific antigen is recognised in the context of the appropriate MHC molecule, and a signalling function in which the recognition event is transmitted across the plasma membrane. However, to induce proliferation and maturation into effector cells, T cells need a second signal in addition to the one mediated by the TcR-CD3 complex. This costimulatory signal is normally provided by the cell surface of APC. Intercellular signalling after TcR/MHC-peptide interaction in the absence of the costimulatory signal results in T cell inactivation, which is known as T cell anergy or T cell unresponsiveness. Several accessory molecules present on the cell surface of T cells with known ligands on the APC have been implicated in providing the costimulatory signal in T cell activation.

The B7-CD28 costimulatory pathway:

The best candidate costimulatory signal leading to full T cell activation, is generated by interaction of CD28 on the T cells with the B7 costimulatory molecules on APC. *In vitro* studies have demonstrated that signalling via the CD28 costimulatory pathway can prevent the induction of anergy.

To date, two members of the B7 family have been molecularly cloned and functionally characterized: B7.1 (CD80), originally named B7/BB1 and a second B7 molecule, named B7.2 or B7.2 (CD86). CD80 is a monomeric transmembrane glycoprotein with an apparent molecular mass of 45-65 kDa and is, like CD28, a member of the immunoglobulin superfamily (Freeman et al., *J. Immunol.* 143: 2714 (1989)). Initially it was reported that the expression of the CD80 molecule was restricted to activated B cells and monocytes stimulated with IFN- γ (Freedman et al., *Cell Immunol.* 137: 429 (1991)). More recently, CD80 expression has also been found on cultured peripheral blood dendritic cells (Young et al., *J. Clin. Invest.* 90:229 (1992)) and on *in vitro* activated T cells (Azuma et al., *J. Exp. Med.* 177:845 (1993)). CD86 is a transmembrane glycoprotein with an apparent molecular mass of approximately 70 KDa and is also a member of

the immunoglobulin superfamily (Freeman et al., *Science* 262:909 (1993)); Azuma et al., *Nature* 366:76 (1993)). The CD86 molecule seems to have a very similar distribution pattern to CD80, with the exception that induction of cell-surface expression seems to be faster and that it is present on freshly isolated monocytes.

It is clear from the literature that blocking CD80 exclusively only results in partial inhibition of T cell activation. Activation of T cells by alloantigen-expressing monocytes is predominantly dependent on CD86 costimulation. During an MLC with monocytes as stimulator cells, anti-CD86 Mab alone could strongly but not completely inhibit the proliferative response. However, only CTLA4-Ig (a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 linked to human IgG [CH2 and CH3 domains], that can bind to both CD80 and CD86) or a combination of anti-CD80 plus anti-CD86 Mabs gave maximal inhibition.

CD40-CD40L costimulatory pathway:

From the above reviewed literature data it appears that other costimulatory molecules can be of crucial importance for the activation of T cells when costimulation via CD80/CD86-CD28 is blocked. One such an alternative costimulatory pathway is regulated by the interaction between CD40 on the APC and CD40L on the T cells. The CD40 molecule belongs to the TNF receptor family of type I transmembrane proteins. The members of this gene family, which include: the two receptors for TNF; the low-affinity nerve growth factor receptor; the T cell activation antigen CD27; CD30 and CD95, are characterized by sequence homology in their cysteine-rich extracellular domains (Armitage et al., *Current Opinion in Immunology* 6:407 (1994)). Interestingly, the known ligands for the members of the TNF receptor family are very homologous as well, forming another gene family named the TNF/CD40L gene family. Although TNF- α is a soluble cytokine, it is initially synthesized as a membrane associated molecule. Most of the members of the TNF/CD40L receptor family are type II transmembrane proteins.

CD40 is best known for its function in B cell activation. The molecule is constitutively expressed on all B cells. CD40L-CD40 interaction can stimulate the proliferation of purified B cells and, in combination with cytokines, mediate immunoglobulin production. Recent studies indicate that the distribution of the CD40 molecule is not so restricted as was originally postulated. Freshly isolated human monocytes express low levels of the CD40 molecule, which can be up-regulated by culturing in the presence of IFN- γ (Alderson et al., *J. Exp. Med.* 178:669 (1993)). Stimulation of monocytes via CD40 results in the secretion of pro-inflammatory

cytokines such as IL-1 and TNF- α , toxic free radical intermediates such as nitric oxide, and up-regulation of the B7 costimulatory molecules. Human dendritic cells (DC) isolated from peripheral blood can also express the CD40 molecule (Caux et al., *J. Exp. Med.* 180:263 (1994)). Ligation of CD40 on DC results in enhanced survival of these cells when cultured *in vitro*. In addition, like with monocytes, stimulation of DC results in secretion of pro-inflammatory cytokines such as IL-1 and TNF- α and up-regulation of the CD80/86 co-stimulatory molecules.

All the above described observations clearly indicate that the CD40L molecule on activated T cells is an important effector molecule that mediates stimulatory effects via ligation of CD40 expressed on a variety of cell types involved in the immunoinflammatory response. However, there is also experimental evidence that the CD40L molecule can receive signals that result in the costimulation of the T cell itself. Using mouse P815 cells that can present anti-CD3 monoclonal antibody to human T cells via binding to Fc-receptors on its cell surface, it was demonstrated that CD40 transfected P815 cells could substantially induce proliferation and CTL activity of small resting human T cells (Cayabyab et al., *J. Immunol.* 152:1523 (1994)). This demonstrates that the CD40L-CD40 interactions is clearly bi-directional.

Prolonged transplant survival after blocking CD80/CD86-CD28:

Several recent *in vivo* models have shown that induction of prolonged graft acceptance is possible by interruption of the CD80/CD86-CD28 pathway. Treatment with CTLA-4 immediately after xenogeneic human pancreatic islet transplantation in mice resulted in long-term graft survival (Lenschow et al., *Science* 257:789 (1992)). However, 90% of fully mismatched rat cardiac allografts were rejected in rats treated intraperitoneally (IP) with CTLA4-Ig during 7 days (Turka et al., *Proc. Natl. Acad. Sci. USA* 89:11102 (1992)). CTLA4-Ig given intravenously (IV) at time of transplantation and then IP every other day on days 2 through 12, prolonged cardiac allograft survival in mice, but failed to prolong the survival of primary skin grafts (Pearson et al., *Transplantation* 57: 1701 (1994)). Blockage of the CD28-pathway with CTLA4-Ig resulted in significant prolongation of small bowel transplant survival in rats compared to controls, although all grafts were rejected after 15 days (Pescovitz et al., *Transplant Proc.* 26:1618 (1994)). Finally, treatment with CTLA4-Ig could reduce lethal murine GVHD in recipients of fully allogeneic bone marrow and significantly prolonged survival rates with up to 63% of mice surviving greater than 3 months post-transplantation (Blazar et al., *Blood* 83:3815 (1994)). The failure of CTLA4-Ig alone to induce anergy *in vitro* and *in vivo*, can most likely be explained by a persistent IL-2 production, induced by TCR triggering in combination with signalling from other accessory

molecules on APC.

Prolonged transplant survival after blocking CD40-CD40L:

Recent work has also demonstrated that blocking the CD40-CD40L pathway is strongly immunosuppressive in transplantation models. Combined treatment with allogeneic small lymphocytes or T cell-depleted small lymphocytes plus an antibody to mouse CD40L permitted indefinite pancreatic islet allograft survival in 37 out of 40 recipients that differed in major and minor histocompatibility loci (Parker et al., *Proc. Nat. Acad. Sci. USA* 92:9560 (1995)). From these experiments it was concluded that the effective blocking of the CD40L-CD40 interaction most likely had resulted in preventing the induction of costimulatory molecules on the small resting lymphocytes by the alloreactive host T cells. In another recent study, it was demonstrated that administration of a blocking Mab to mouse CD40L at the time of transplantation markedly prolonged survival of fully disparate murine cardiac allografts in both naive and sensitized hosts. However, when anti-CD40L therapy was delayed until postoperative day 5, anti-CD40L failed to prolong graft survival. From this study, it was concluded that anti-CD40L therapy inhibited allograft rejection primarily by interfering with T cell help for effector functions.

Long-term acceptance of allografts without signs of chronic rejection after blocking CD80/CD86-CD28 and CD40-CD40L:

Blocking either of the two major T cell costimulatory pathways, CD80/86-CD28 or CD40-CD40L, alone is not sufficient to permit indefinite engraftment of highly immunogenic allografts. However, it was recently shown that blocking the CD80/CD86-CD28 and CD40-CD40L pathways simultaneously effectively aborts T cell clonal expansion *in vitro* and *in vivo*, promotes long-term survival of fully allogeneic skin grafts, and inhibits the development of chronic vascular rejection of primarily vascularized cardiac allografts (Larsen *et al.*, *Nature* 381:434 (1996)). In the vascularized murine cardiac allograft model, C3HJ recipients treated with CTLA4-Ig alone (Mean Survival Time (MST) 50d), anti-CD40L Mab alone (MST 70d), or the combination (MST >70d), all showed prolonged survival of BALB/c cardiac allografts compared with untreated controls (MST 12d). Interestingly, when examined histologically at day 58-62 post-transplantation, marked differences were apparent. Allografts from CTLA4-Ig-treated mice showed extensive lymphocytic infiltration, interstitial fibrosis, and severe coronary arterial intimal thickening and fibrosis, all clear signs of a chronic rejection process. Anti-CD40L-treated recipients had less lymphocytic infiltration and interstitial fibrosis, but also had coronary vasculopathy characteristic of chronic rejection. In contrast, the allografts from mice in which the

CD80/86-CD28 and CD40-CD40L pathways were blocked simultaneously, the parenchyma and blood vessels were virtually indistinguishable from those found in normal BALB/c hearts.

Current concepts on immunological tolerance hold that anergy is the result of intercellular signalling after TcR/MHC-peptide interaction, in the absence of a so-called co-stimulatory signal. As described above, both the CD80/CD86-CD28 costimulatory pathway and the CD40L-CD40 costimulatory pathway are important for the activation of T cells and play a role in the prevention of anergy. Stimulation of T cells via the TcR/CD3 complex results in a low and transient expression of CD40L. It has previously been demonstrated that stimulation of T cells via TcR/CD3 and costimulation with CD80/CD86-CD28 results in a strong and prolonged expression of the CD40L molecule. Low levels of CD86 can be found constitutively on various APC populations. Furthermore, stimulation of APC via CD40 is one of the strongest signals to up-regulate CD80 and CD86. Likewise, low levels of CD40L are expressed on T cells after first encounter of antigen (TcR/CD3 activation), even without complete costimulation. This CD40L expression can not only receive a signal from the APC via CD40, but can also stimulate the APC to enhance the CD86 expression and most importantly up-regulate CD80 expression. At the same time, low levels of CD86 expression on professional APC can prevent the induction of T cell anergy and up-regulation of CD80 and CD86 expression strongly stimulates the T cells to secrete cytokines and to enhance CD40L expression. It is therefore concluded by the present inventors that these two interactions (CD40L-CD40 and CD80/CD86-CD28) are connected in the initiation and amplification of T cell mediated immune responses. Thus, only blocking the CD40L-CD40 interaction will not completely prevent activation of the T cells via CD80/CD86-CD28, and only blocking the CD80/CD86-CD28 interaction will not completely prevent the activation of the effector functions of the APC population. For optimal immunosuppression, the CD80/CD86-CD28 and CD40L-CD40 interaction need to be blocked simultaneously.

In the above described *in vivo* experiments a combination of a monoclonal antibody to mouse CD40L was used in combination with CTLA4-Ig to block both CD80 and CD86. However, the generation of a single pharmaceutical agent by combining the ligand binding domains of CTLA4-Ig and that of an anti-CD40L monoclonal antibody will result in the cross-linking of T cells and APC. This will undoubtedly result in the activation of the T cells, which is exactly the opposite of the desired effect. Furthermore, all of the above referenced publications clearly suggest that blocking both CD80 and CD86 results in a better immunosuppression than blocking each of them separately. Also, it has been demonstrated that only blocking both CD80

and CD86 can result in T cell anergy. It was therefore surprising to find that in combination with an antagonistic anti-CD40 monoclonal antibody, blocking only CD86 resulted in T cell anergy despite the fact that CD80 was not blocked. This had led to the present invention that consists of pharmaceutical molecules that have the capacity to bind and block both the CD40 and the CD86 molecules.

Summary of the Invention

The invention is based on the discovery that a molecular combination of an antagonistic molecule binding to CD40 and an antagonistic molecule binding to CD86, both expressed at low levels on professional APC, can inhibit the activation of T cells and result in T cell anergy. Accordingly, this combination can be used to prevent or treat diseases or conditions in which the activation of T cells is involved, including transplant rejection, multiple sclerosis, psoriasis, rheumatoid arthritis and systemic lupus erythematosus

One embodiment of this invention is a single soluble molecule or ligand capable of binding to the human CD40 and CD86 antigens located on the surface of antigen presenting cells. A preferred embodiment is a single protein encompassing a combination of a therapeutically active antagonistic monoclonal antibody to CD40 or fragments thereof and a therapeutically active antagonistic CD86 ligand, including a monoclonal antibody to CD86, the CTLA4-Ig molecule, or fragments thereof. In a related embodiment, gene therapy techniques are used to produce such a single protein *in vivo*.

A more preferred embodiment is a single protein encompassing a combination of a therapeutically active antagonistic monoclonal antibody to CD40 or fragments thereof and the therapeutically active antagonistic anti-CD86 monoclonal antibody Fun-1 (Nozawa et al., *J. Pathol.* 169:309 (1993)) or a therapeutically active fragment thereof. Again, gene therapy can be used to produce such single protein *in vivo*.

Detailed description of the invention

All publications and applications, cited previously or below are hereby incorporated by reference. One embodiment of the bispecific molecules of the invention is formed by conjugating two single chain antibodies, one derived from an antibody specific for CD40 and the other from an antibody specific for an CD86. Another embodiment is a fusion protein including a monoclonal antibody to CD40, or a fragment thereof, and an antibody to CD86, or a fragment thereof. In either case, a CTLA4-Ig molecule can be substituted for the antibody to CD86. The monoclonal antibodies used to form the bispecific molecules include,

in whole or in part, as appropriate, chimeric antibodies, humanized antibodies, human antibodies, single-chain antibodies and fragments, including Fab, F(ab')₂, Fv and other fragments which retain the antigen binding function of the parent antibody. Single chain antibodies ("ScFv") and the method of their construction are described in U.S. Patent No. 4,946,778.

Chimeric antibodies are produced by recombinant processes well known in the art, and have an animal variable region and a human constant region. Humanized antibodies correspond more closely to the sequence of human antibodies than do chimeric antibodies. In a humanized antibody, only the complementarity determining regions (CDRs), which are responsible for antigen binding and specificity, are non-human derived and have an amino acid sequence corresponding to the non-human antibody, and substantially all of the remaining portions of the molecule (except, in some cases, small portions of the framework regions within the variable region) are human derived and have an amino acid sequence corresponding to a human antibody. See L. Riechmann et al., Nature; 332: 323-327 1988; U.S. Patent No. 5,225,539 (Medical Research Council); U.S. Patent Nos. 5,585,089; 5,693,761; 5,693,762 (Protein Design Labs, Inc.).

Human antibodies can be made by several different methods, including by use of human immunoglobulin expression libraries (Stratagene Corp., La Jolla, California; Cambridge Antibody Technology Ltd., London, England) to produce fragments of human antibodies (V_H, V_L, Fv, Fd, Fab, or (Fab')₂) and use of these fragments to construct whole human antibodies by fusion of the appropriate portion thereto, using techniques similar to those for producing chimeric antibodies. Human antibodies can also be produced in transgenic mice with a human immunoglobulin genome. Such mice are available from Abgenix, Inc., Fremont, California, and Medarex, Inc., Annandale, New Jersey. In addition to connecting the heavy and light chain Fv regions to form a single chain peptide, Fab can be constructed and expressed by similar means (M.J. Evans et al., J. Immunol. Meth., 184:123-138 1995).

All of the wholly and partially human antibodies described above are less immunogenic than wholly murine or non-human-derived antibodies, as are the fragments and single chain antibodies. All these molecules (or derivatives thereof) are therefore less likely to evoke an immune or allergic response. Consequently, they are better suited for *in vivo* administration in humans than wholly non-human antibodies, especially when repeated or

long-term administration is necessary, as may be needed for treatment with the bispecific antibodies of the invention.

U.S. Patent No. 5,534,254 (Creative Bimolecules, Inc.) describes several different embodiments of bispecific antibodies, including linking single chain Fv with peptide couplers, including Ser-Cys, (Gly)₄-Cys, (His)₆-(Gly)₄-Cys, chelating agents, and chemical or disulfide couplings including bismaleimidohehexane and bismaleimidocaproyl. Another embodiment is a dimer having single chain FvL₁ and FvH₂ linked and FvH₁ linked with FvL₂. All such linkers and couplings can be used with the bispecific antibodies of the invention.

The bispecific molecules of the invention are administered as a pharmaceutical composition at a dosage effective to inhibit the activation of T cells. The effective dosage can be readily determined in routine human clinical trials or by extrapolation from animal models. The dosage and mode of administration will depend on the individual. Generally, the compositions are administered at a dose between 0.1 mg/kg and 10 mg/kg. Typically, the pharmaceutical composition is administered by injection, either intravenously, subcutaneously or intraperitoneally. It may also be possible to obtain compositions which may be topically or orally administered, or which may be capable of transmission across mucous membranes. If administered by continuous infusion, the infusion may proceed at a dose between 0.05 and 1 mg/kg/hour.

Before administration to patients, formulants and excipients, well known in the art, are preferably added to the pharmaceutical composition. Additionally, pharmaceutical compositions can be chemically modified by covalent conjugation to a polymer to increase their circulating half-life. Polymers, and methods to attach them to peptides, are shown in U.S. Patent Nos. 4,766,106; 4,179,337; 4,495,285; and 4,609,546, and include polyoxyethylated polyols and PEG.

Monoclonal antibodies against human CD40 are described in U.S. Patent No. 5,677,165. Antibodies against CD86 can be made by similar methods. The CTLA4-Ig molecule can be made by methods well known in the art. These peptides can be linked to a carrier, for example, keyhole limpet hemocyanin, to increase the immunogenicity and the production of antibodies to the immunogen.

The present invention will now be illustrated by reference to the following examples which set forth particularly advantageous embodiments. However, it should be noted that these

embodiments are illustrative and are not to be construed as restricting the invention in any way.

Brief Description of the Figures

Figure 1 shows a schematic drawing of the first step in the diabody construction, exchange of the V-regions.

Figure 2 shows a schematic drawing of the exchange of the linker, the second step in the diabody construction.

Figure 3 shows a schematic drawing of the strategy applied for cloning of the anti-CD40/anti-CD86 diabody.

Figure 4 shows a BIAcore sensogram showing the capability of the diabody to bind the CD86-Ig and CD40-Ig antigen simultaneously. From the periplasmic fraction, injected at $t=110$ (sec) on a surface containing 6537 Response Units (RU) CD86-Ig, 1300 RU diabody was captured at $t=230$ (sec), as can be seen by the difference in response after the first wash and the normalized signal before injection. At $t=360$ (sec) CD40-Ig was injected during 120 sec. The diabody, arrested with one binding domain to the CD86-Ig, reacted with the other domain to CD40-Ig yielding 550 RU captured antigen (difference in signal between the second wash at $t=480$ (sec) and before the second injection at $t=360$ (sec)).

Figure 5 shows the results of a T cell activation experiments in which T cells are stimulated with allogeneic monocytes. T cell activation is partially inhibited by blocking CD80 and CD86 with CTLA4-Ig or an antagonistic anti-CD40 monoclonal antibody M3 alone, but almost completely blocked when CTLA4-Ig and antagonistic anti-CD40 monoclonal antibody M3 are combined.

Figure 6 shows the results of a T cell restimulation experiments in which T cells are stimulated with allogeneic monocytes in the presence of blocking agents during primary stimulation and analysed for proliferative capacity during restimulation in the absence of blocking agents. The presence of CTLA4-Ig alone only results in a slight alloantigen-specific hypo-responsiveness, whereas the combination of CTLA4-Ig with CsA or the antagonistic anti-CD40 monoclonal antibody M3 results in T cell unresponsiveness. T cell responses to the control third-party alloantigen-expressing monocytes is not affected. Closed bars are the T cell responses to the alloantigen used in the primary culture, open bars represent T cell responses to third-party alloantigen-expressing monocytes.

Figure 7 shows the results of a T cell restimulation experiments in which T cells are

stimulated with allogeneic PBMC in the presence of blocking agents during primary stimulation and analysed for proliferative capacity during restimulation in the absence of blocking agents. The presence of antagonistic monoclonal antibody to CD40 and antagonistic monoclonal antibody to CD86, with or without antagonistic monoclonal antibody to CD80 results in alloantigen-specific T cell unresponsiveness. The presence of antagonistic monoclonal antibody to CD40 alone or in combination with antagonistic monoclonal antibody to CD80 only results in partial inactivation of the T cells.

Examples

Materials and Methods:

CD40 and CD86 extracellular domain Ig fusion proteins

In several experiments fusion proteins of lymphocyte cell surface receptors and the Fc-region of human IgG were used. These extracellular domain (ED) fusion proteins (ED-Ig fusion proteins) have been generated by fusion of the nucleic acid sequence encoding the extracellular domain of the cell surface receptors generated by PCR amplification based on published cDNA sequences to the CH1/hinge-CH3 region (Fc) of human IgG1 based on the sequence by Ellison et al. (*NAR* 10:4071 (1982)). ED-Ig fusion proteins were expressed in Sf9 insect cells and were used as conditioned medium or after purification by affinity chromatography using protein A.

Cell lines and culture conditions

The B-cell line JY was cultured in T75 culture flasks routinely (Costar, Cambridge, MA, USA) in Iscove's modified Dulbecco's medium (IMDM) to which 50 µg/ml gentamycin and 10% foetal calf serum was added (FCS) (Hyclone, Logan, Utah USA). The cells were cultured in a humidified incubator at 37°C and 5% CO₂. Every week the cells were split (1/20 to 1/100). To store the cell line, ampoules were made containing 5-10 x 10⁶ cells/ml Hank's balanced salt solution HBSS supplemented with 20% FCS and 10% DMSO and stored in the liquid nitrogen.

Lymphocyte isolation and stimulation

Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood from healthy donors by Ficoll-Hypaque density centrifugation and re-suspended in complete medium consisting of RPMI 1640 (Gibco, Paisley, UK) supplemented with 2 mM L-Glutamine, streptomycin (100 mg/ml), penicillin (100 U/ml) and 5% heat-inactivated autologous plasma. Enriched monocyte preparations were prepared by rosetting of PBMC with AET-treated sheep red blood cells and removal of E-rosetting cells on Ficoll-Hypaque density gradients, followed by

cold aggregation of monocytes as essentially described by Zupo et al. (*Eur. J. Immunol.* 21:351 (1991)). T cells were further purified from the PBMC preparations by depletion of monocytes, B cells and NK cells using Lympho-Kwik T (One Lambda, Los Angeles, CA, USA) according to the manufacturers protocol.

For primary mixed lymphocyte cultures with enriched monocytes and purified T cells, $0.5-1 \times 10^6/\text{ml}$ purified T cells and $0.1-0.2 \times 10^6/\text{ml}$ monocytes were cultured in 200 ml complete culture medium in 96-well plates for 6 days in the presence or absence of blocking agents in concentrations ranging from 1-10 $\mu\text{g}/\text{ml}$. For the last 8 hours of the culture period, cells were pulsed with 1 mCi $[3\text{H}]$ -thymidine (Amersham International, Amersham, UK). Cells were harvested on glass fiber filters by using a Skatron automatic cell harvester, and radioactivity on the paper was counted in a liquid scintillation counter. For re-stimulation experiments, the T cells ($0.5-1 \times 10^6/\text{ml}$) and monocytes from the same donor (0.1 to $0.2 \times 10^6/\text{ml}$) were cultured for 6 days in 1 ml complete medium in 24-well plates in the presence or absence of blocking agents in concentrations ranging from 1-10 $\mu\text{g}/\text{ml}$ and in the presence or absence of cyclosporin A (CsA) at a concentration of 400 ng/ml. After 6 days, the remaining cells were collected and cultured for an additional 2 days, before re-stimulation for 3 days in the absence of blocking agents. T cell proliferation was determined as described above for primary mixed lymphocyte cultures.

Mixed lymphocyte cultures were also performed with non-separated PBMC. In these experiments, fresh PBMC ($1 \times 10^6/\text{ml}$) as responder cells and PBMC that were pre-activated with human IL-4 (20 $\mu\text{g}/\text{ml}$) and human GM-CSF (100 U/ml) ($0.1 \times 10^6/\text{ml}$) as stimulator cells were cultured for 6 days in 1ml complete culture medium in 24-well plates in the presence or absence of blocking agents in concentrations ranging from 1-10 $\mu\text{g}/\text{ml}$. After 6 days the remaining cells were collected and cultured for an additional 3 days, before the allo-reactive T cells were re-stimulated with the same PBMC that were pre-activated with human IL-4 (20 $\mu\text{g}/\text{ml}$) and human GM-CSF (100 U/ml) ($0.1 \times 10^6/\text{ml}$) as stimulator cells for 3 days in the absence of blocking agents. T cell proliferation was assayed by $[3\text{H}]$ -thymidine incorporation as described above.

Polymerase chain reaction

To amplify DNA fragments, polymerase chain reactions (PCR) were performed. A typical PCR reaction mix contained: 0-10 mM MgCl_2 , 50 mM KCl, 10 mM Tris-HCl pH 9.0, 1.0% Triton X-100, 0.25 mM dNTP each, 25 pmol primer/100 μl reactions mix, 1-1000 ng DNA/100 μl reaction mix and 2.5 U Taq polymerase. Reactions were run using a Perkin Elmer thermocycler (Perkin Elmer Corp, Norwalk CT). A standard PCR scheme consisted of one step

for 2-5 min at 95°C to denature the DNA, followed by 20-40 cycles of 1 min at 95°C, 1 min at 55°C and 1-4 min at 72°C. After the final step an extension step was performed for 7 min at 72°C.

Flow cytometric analysis (FACS)

Cells ($0.1-0.2 \times 10^6$ /sample) were incubated for 20 min at 4°C with the specific monoclonal antibody (0.1-1 mg/sample). After washing with FACS buffer (PBS pH 7.4 1% BSA 0.1% NaN₃), the cells were incubated for another 20 min at 4°C with goat anti-mouse antibodies conjugated to fluorescein isothiocyanate (FITC) or phycoerythrin (PE). The cells were washed with FACS buffer and finally suspended in FACS buffer containing 0.5% paraformaldehyde and analysed with a FACScan flow cytometer (Becton Dickinson). The specific binding of the monoclonal antibodies is expressed as the mean fluorescent intensity in arbitrary units. A similar protocol was used to test the single chain antibody expressing phage particles. In this case detection was done by using an un-conjugated sheep anti-M13 antibody (Pharmacia AB, Uppsala Sweden), followed after washing by incubation with donkey anti-sheep conjugated to FITC (Sigma Chemical Co. St. Louis, MO, USA). Likewise a similar protocol was used to demonstrate the biological activity of the diabody and triabody constructs. In these experiments detection was done by incubation of the cells with the diabody or triabody constructs followed by incubation with one of the ED-Ig fusion proteins, followed by incubation with an FITC-conjugated anti-human IgG antiserum.

SDS-PAGE and Western blotting analysis

To analyse the expressed constructs SDS-PAGE and Western blot analysis was performed. Briefly, samples were boiled for 5 min in 0.8% sodium dodecyl sulfate (SDS) and 1 mM dithiothreitol (DTT). Subsequently the samples were run on a 15% SDS-polyacrylamide gel electrophoresis (SDS-PAGE; 2h 100V). After electrophoresis the gel was electroblotted to a nitrocellulose filter or stained with 0.1% coomassie blue in 10% methanol and 10% acetic acid. Electroblotting was done in 25 mM Tris-HCl, 192 mM glycine and 10% methanol pH 8.3 for 1h at 100V; 4°C. After blotting the nitrocellulose filter was blocked with 1% BSA in PBS-Tween (0.05%) for 1hour at room temperature. Subsequently the blot was incubated at room temperature in PBS-Tween with a anti c-myc antibody for detection. After incubation with a second antibody (peroxidase labelled), the blots were stained by 4-chloro-naphtol.

BIACore analysis

Analysis were performed on the Pharmacia Biosensor 2000. The CM chip was activated with 0.2M EDC/0.05M NHS for 5 min. Subsequently coupling of ligand was done in 10mM NaAc pH5.0 during 5 min (0.1 mg Ig construct/ml). This was followed by loading of the ScFv, Mab or dia/triobody constructs in various concentrations in PBS buffer. In case of the dia/triobody constructs the chip was washed followed by loading of the second Ig construct. The sensor surface was regenerated with 0.1M NaOH.

Example 1

Single chain antibody fragments expressing phage from monoclonal antibodies to human CD40 and CD86 were generated as follows. For the generation of a single chain antibody fragment (ScFv) of the anti-CD40 monoclonal antibody 5D12 both the VH and VL region were amplified by PCR, followed by a second assembly PCR to connect both regions. For this purpose 4 primers were designed (SEQ ID NO:1-4). SEQ ID NO:1 contains a HindIII and SfiI restriction site for cloning purposes followed by a degenerated sequence annealing to the 5' VH region of 5D12. SEQ ID NO:2 contains a degenerate sequence for the 3' part of the VH region followed by a sequence encoding a ((Gly)₄Ser)₃ linker and the 5' part of the VL regions. SEQ ID NO:3 is a degenerated primer having homology with the 5' part of the VL region, while the last primer (SEQ ID NO:4) contains a NotI restriction site and anneals to the 3' part of the VL region. Briefly, these primers were used to separately PCR amplify the VH and VL regions of monoclonal antibody 5D12. As template for this PCR reaction we used a plasmid containing the VH or VL regions of 5D12 (VH: SEQ ID NO:5 and VL: SEQ ID NO:6). The cDNA obtained in this PCR step was gel purified and used in an assembly PCR resulting in the linkage of the V region through the (Gly₄Ser)₃ linker. Subsequently the obtained single chain 5D12 construct was digested with the restriction enzymes HindIII and NotI, followed by ligation in pGEM-13Zf (Promega Madison USA). The ligation was transformed in DH5 α and plated on LB plates. By sequencing of several clones, a correct 5D12 ScFv clone was found (SEQ ID NO:7).

For the generation of ScFv's reactive with human CD86, the same primer set as for 5D12 was used. All the steps in the generation of the ScFv of the anti-CD86 monoclonal antibody Fun-1 were performed as described above for the 5D12 ScFv reactive with human CD40. The V regions of Fun-1 (VH: SEQ ID NO:8; VL: SEQ ID NO:9) were used as template to obtain the anti-CD86 ScFv construct (SEQ ID NO:10).

Example 2

Construction of bi-specific diabody molecules capable of binding to human CD40 and human CD86:

Bi-specific bivalent molecules were generated by shortening the flexible linker sequence in the anti-CD40 ScFv and in the anti-CD86 ScFv, from fifteen residues to five (Gly₄Ser) and by cross-pairing the variable heavy and light chain domains from the two single chain Fv fragments with the different antigen recognition. The construction was performed in three steps. The light chain variable fragments were exchanged in the ScFv constructs from anti-CD86 (aCD86) and anti-CD40 (aCD40) by using restriction enzyme sites located in the 5' end (SacI at nucleotide numbers 7 to 12 of VL) and just outside the 3' part of the light chain variable gene (NotI) (see Figure 1). In the following step the 15-residue linker of the chimeric constructs VH-aCD86/15AA-linker/VL-aCD40 (coded 7.2/15/40) and VH-aCD40/15AA-linker/VL-aCD86 (coded 40/15/7.2) was replaced by the 5 residue linker (Gly₄Ser) by using sites located in the 3' part of VH (Bsu361 at nucleotide number 335 of the anti-CD40 VH or at 371 of the anti-CD86 VH to number +2 in the linker sequence) and the 5' part of VL end (SacI at nucleotide number 7 to 12 both VL's) (see Figure 2). Finally, both chimeric cassettes were combined in the vector pUC119-fabsol (a pUC119 derivative similar to pUC119His6mycXba (Low et al., *J. Mol. Biol.* 260:359 (1996)), but with all Apall-sites in the vector backbone deleted by *in vitro* mutagenesis) containing a bi-cistronic expression cassette. The subcloning was performed in two steps. First, the aCD86/5AA-linker/ aCD40-construct was cloned in pUC119-fabsol using the restriction sites SfiI and NotI. Subsequently the ScFv cassette of aCD40/5AA-linker/aCD86 was amplified with the following oligonucleotide primers: 5'-TCT CAC AGT GCA CAG GTG CAG CTG CAG GAG TCT GG-3' (SEQ ID NO:11) and 5'-CGT GAG AAC ATA T GG CGC GCC TTA TTA CCG TTT GAT TTC CAG GTT GGT GCC-3' (SEQ ID NO:12). These primers contain an ApaLI-and an AscI-site respectively (underlined). The amplified PCR-fragment was digested with ApaLI and AscI, and ligated in the pUC119-fabsol plasmid containing the aCD86/5AA-linker/aCD40-construct. A diabody-producing clone containing both ScFv cassettes was identified and used for expression of the recombinant diabody molecule (pUC119-fabsol-CD40/CD86) (5D12VH + FUNVL: SEQ ID NO:13; FUNVH + 5D12VL: SEQ ID NO:22).

The whole cloning strategy to obtain the bi-specific diabody molecule based on antagonistic anti-CD40 Mabs and antagonistic anti-CD86 Mab Fun-1, capable of binding to human CD40 and human CD86 molecule on antigen presenting cells, is summarized in Figure 3.

The same procedure is also used for the generation of a bi-specific diabody molecule based on antagonistic anti-CD40 Mabs and antagonistic Mabs reactive with both CD80 and CD86, capable of binding to human CD40, human CD80 and human CD86 molecule on antigen presenting cells.

Example 3

Expression, isolation and characterization of bi-specific diabody molecules capable of binding to human CD40 and human CD86:

For the production of the bi-specific diabody molecule capable of binding to human CD40 and human CD86, the plasmid containing the aCD86/aCD40-bicistronic expression cassette described in Example 2 above was used. Fifty ml of 2YT medium (100 µg/ml amp, 0.1% glucose) was inoculated (1 v/v %) with a saturated culture (16 hours grown at 30 °C). After 5 hours growth at 30°C and with a culture having an optical density at 600 nm of 0.9, the diabody production was induced by adding IPTG to a concentration of 1 mM. Cultivation was continued for 4 hours at 20°C and the cells from 15 ml culture were pelleted (10 minutes at 1100g at room temperature). Supernatant and cells were stored at -20 °C until further processed. The remaining 35 ml culture was grown at 20°C for another 16 hours. Cells were pelleted as described above. Periplasmic fractions were prepared by resuspending the cells in 0.53 ml cold TES-buffer (20 mM Tris-HCl; 0.5 mM EDTA; 0.5 M sucrose pH 8.0). The mixture was incubated for 2 minutes on ice, subsequently 0.59 ml cold three fold diluted TES was added and the incubation was prolonged for 30 minutes. The spheroplasts were centrifuged for 15 minutes at 1100g at 4 °C and the supernatant containing the periplasmic proteins was collected. The pellet fraction was resuspended in 0.75 ml TES/MgSO₄ (TES-buffer; 15 mM MgSO₄) and incubated for 30 minutes on ice. Spheroplasts were pelleted for 15 minutes at 1100g at 4°C and the supernatant added to the first supernatant fraction. The total periplasmic fraction was cleared again (15 minutes at 1100g at 4°C) and dialyzed against PBS. All fractions were analyzed on PAGE and Western blot with the anti-c-myc antibody for detection. The highest concentration of ScFv was found in the periplasmic fraction prepared from the culture after 4 hours induction, and to some degree in the medium fraction of the culture induced for 20 hours. The functionality of the produced diabody was tested in BIAcore. Purified CD86-Ig was immobilized on the surface of a CM-chip, yielding 6500 RU (Response Units) of coupled protein. Injection of the periplasmic fraction for 120 sec with a flow rate of 10 µl/min resulted in the capture of approx. 1200 RU diabody. Subsequently CD40-Ig was injected under the same conditions as the diabody resulting in the binding of an additional 540 RU antigen. This experiment demonstrated the capability of the produced diabody

molecule to bind CD40 and CD86 simultaneously (see Figure 4).

Example 4

Construction of bi-specific and tri-specific triabody molecules capable of binding to human CD40 and CD86 or human CD40, CD80 and CD86:

The construction of bi-specific and tri-specific triabody molecules is analogous to the scheme described above for the diabody, except that the linker has to be deleted (zero residue linker). This is accomplished by *in vitro* mutagenesis, using single stranded phagemid DNA and oligonucleotides encoding the mutation. Using ScFv constructs of antagonistic monoclonal antibodies to human CD40, CD80 and CD86 at least two gene constructs are possible: (i) VH α CD40/0/VL α CD80-VH α CD80/0/VL α CD86-VH α CD86/0/VL α CD40 and; (ii) VH α CD40/0/VL α CD86-VH α CD86/0/VL α CD80-VH α CD80/0/VL α CD40. All VH/VL-combinations are made by exchanging VH- and VL-domains in the constructs such as described above for bi-specific diabodies having the 5 amino acid linkers, applying the strategy described above using SfiI and Bsu36I to exchange VH regions, and SacI and NotI to exchange VL regions. Subsequently, the three ScFv-cassettes are cloned in a single expression module encoding a tricistronic mRNA. This DNA will serve as template for an oligo-directed *in vitro* mutagenesis procedure, to delete the 5 residue linker in one up to three VH-VL-pairs. The various triabodies that are made, may differ in binding characteristics due to other orientations of the ScFv domains and in linker length. Only one of the three ScFv cassettes is provided with the previously mentioned tag sequences. In order to drive triabody formation as well as to maintain stability, disulfide bridges can be introduced by adding cysteine residues at the carboxyterminus or within the V-regions.

Example 5

Construction of a fusion molecule consisting of an antagonistic anti-CD40 monoclonal antibody linked by its C-terminal residue to the extracellular domain of human CTLA4 capable of binding to CD40, CD80 and CD86 can be carried out as follows. The conceptual therapeutic agent is a fusion protein combining the high affinity and specificity of CTLA4 for both CD80 and CD86 with an antagonistic anti-CD40 monoclonal antibody. This fusion molecule is produced in stable, active form as a complete anti-CD40 monoclonal antibody to which the extracellular domain of human CTLA4 (CTLA4ED) is C-terminal linked by a flexible linker. The construction of the anti-CD40 antibody attached by its Fc part to the extracellular domain of CTLA4 is done by the following PCR and cloning steps. The VH and CH1 regions of anti-CD40

together with a leader sequence are amplified using the oligonucleotides 5' GCG CGA ATT CAT GGA CAT GAG GGT CCC CGC 3' (SEQ ID NO:14) and 5' AGA TTT GGG CTC AAC TTT CTT GTC CAC 3' (SEQ ID NO:15). This is followed by amplification of the CH2 and CH3 regions of human IgG using the oligonucleotides 5'GTG GAC AAG AAA GTT GAG CCC AAA TCT 3' (SEQ ID NO: 16) and 5' GCGC GAA TTC TTA AGC GGC CGC AGA TCC GCC GCC ACC CGA CCC ACC TCC GCC CGA GCC ACC GCC ACC TTT ACC CGG AGA CAG 3' (SEQ ID NO: 17). After removing of the primers a second PCR is done to assemble both PCR products to obtain a full-length 5D12 heavy chain. The obtained PCR product is gel purified and cloned in pCR Script using the Stratagene cloning kit. Briefly, the PCR product is incubated with plasmid together with T4 ligase and SrfI for 1h at room temperature, after which the entire sample is transformed in X11Blue E. coli cells. The cells are plated on LB plates containing 100 µg ampiciline/ml, 20 µg IPTG/ ml and 20 µg Xgal/ml. After incubation o/n at 37°C putative white clones are analyzed for having an insert. Clones containing inserts are analyzed by cycle sequencing using M13 and M13 reverse primers. After confirming the correct sequence, the anti-CD40 heavy chain is cloned using the EcoRI restriction site in the bicistronic baculovirus expression plasmid pAcUW51 (Pharmingen) after the p10 promoter. The in this way obtained construct already contains C-terminal a flexible (Gly₄Ser)₃ linker after which the CTLA4ED part was cloned. Therefore the CTLA4ED part is amplified with the oligonucleotides 5' GCGC GCG GCC GCA ATG CAC GTG GCC CAG CCT G 3' (SEQ ID NO: 18) and 5' GCGC GCG GCC GC CTA GTC AGA ATC TGG GCA CGG TTC 3' (SEQ ID NO: 19) by PCR, gel purified and cloned after the heavy chain of 5D12 using the NotI cloning site. After confirmation by sequence analysis of this step the light chain is cloned. This is done by using a plasmid which already contained the VL region of 5D12 attached to a human CL region. So using the oligonucleotides 5' GCGC GGATCC ATG GAC ATG AGG GTC CCC GC 3' (SEQ ID NO: 20) and 5'GCGC GGATCC CTA ACA CTC TCC CCT GTT GAA GC 3' (SEQ ID NO: 21) the light chain of 5D12 is amplified and cloned in the constructed pAcUW51 expression plasmid using the BamHI cloning site after the polyhedrin promoter. After DNA sequence analysis a correct clone is obtained. After this confirmation, the expression plasmid containing the 5D12-CTLA4ED construct is introduced into Sf9 insect cells along with the viral AcNPV wild-type DNA using the BaculoGold transfection system of Pharmingen. Recombinant virus is plaque-purified and the integrity of the expression cassette is checked by PCR and cycle sequencing. For protein production, insect cells are used. These cells can grow in suspension in serum-free medium, and are the best known secretors of heterologous proteins. The fusion protein is purified from serum-

free conditioned medium by *S. aureus* protein A affinity chromatography (Harlow and Lane, 1988). Purity is checked by SDS-PAGE and by western blotting under reducing and non-reducing conditions to assess the extent of dimerization.

Example 6

Effects of blocking the CD40L-CD40 and/or CD80/86-CD28 pathways on the activation of T cells:

It has been demonstrated extensively that blocking the CD80/86 pathway results in an inhibition of activation of T cells (reviewed in Van Gool et al., *Res. in Immunol.* 146:183 (1995)). However, under a number of circumstances, blocking of the CD80/86 interaction does not result in complete prevention of T cell activation. This is exemplified by Figure 5, in which purified human T cells are stimulated with allogeneic monocytes as detailed above under materials and methods. Addition of CTLA4-Ig (blocking both CD80 and CD86) only resulted in a partial inhibition of the alloantigen-specific T cells. Surprisingly, addition of the antagonistic anti-CD40 monoclonal antibody M3 also resulted in a partial inhibition of T cell activation to the same extent as CTLA4-Ig. Even more surprisingly, the combination of the antagonistic anti-CD40 monoclonal antibody M3 with CTLA4-Ig resulted in nearly complete blockade of T cell activation.

It has also been demonstrated that a blockade of CD80/86 in combination with CsA results in antigen-specific T cell unresponsiveness (reviewed in Van Gool et al., *Res. in Immunol.* 146:183 (1995)). This has been demonstrated in mixed lymphocyte cultures, in which blocking agents were added during a primary stimulation with the alloantigen, followed by a short rest period and subsequent restimulation with the same alloantigen in the absence of blocking agents. Figure 6 indeed shows that addition of CTLA4-Ig plus CsA, but not CTLA4-Ig alone to purified human T cells that are stimulated with allogeneic monocytes results in alloantigen-specific T cell unresponsiveness (solid bars). The response to unrelated third party alloantigen-expressing monocytes is unchanged (open bars). Figure 6 also shows that the addition of CTLA4-Ig plus anti-CD40 monoclonal antibody M3 alone to purified human T cells that are stimulated with allogeneic monocytes also results in alloantigen-specific T cell unresponsiveness (solid bars). Again, this unresponsiveness to the alloantigen of the first culture is specific, since the response to unrelated third party alloantigen-expressing monocytes is unchanged (open bars).

In another set of experiments (Figure 7) it is shown that a combination of blocking CD40 with the antagonistic anti-CD40 monoclonal antibody 5D12 and blocking of CD80 and

CD86 with antagonistic monoclonal antibodies, results in alloantigen-specific T cell unresponsiveness when tested in MLC experiments using PBMCs as detailed above in the materials and methods section. Surprisingly, alloantigen-specific T cell unresponsiveness was also induced when the anti-CD40 monoclonal antibody was combined with the antagonistic anti-CD86 monoclonal antibody without blocking the CD80 costimulatory receptor. In contrast, the combination of the anti-CD40 monoclonal antibody and the anti-CD80 monoclonal antibody, without blocking the CD86 receptor resulted only in T cell hypo-responsiveness to the same level as with the antagonistic anti-CD40 monoclonal antibody alone. This was surprising, since it has extensively been demonstrated that blocking of both CD80 and CD86 always results in more complete inhibition than with either alone. This demonstrates that blocking the CD86-CD28 costimulatory interaction together with blocking the CD40L-CD40 costimulatory interaction with one therapeutic molecule such as described in the above examples has a strong potential for immunotherapy of T cell mediated diseases.

Example 7:

Gene Therapy to Produce the Proteins of the Invention

Another embodiment of the invention includes gene constructs that direct the expression *in vivo* of the diabodies of the invention which bind to the human CD40 and CD86 antigens (or the diabodies or triabodies which bind to human CD40, CD80 and CD86, or the fusion protein including anti-CD40 and CTLA4-Ig) located on the surface of antigen presenting cells. The gene constructs can be introduced by well-known methods using viral vectors, including a retrovirus, an adenovirus, a parvovirus or any other vector permitting cellular transfer of the gene constructs, or by incorporation of the gene construct into liposomes with or without the viral vector. The gene constructs can also be transfected into cells *ex vivo*, using known methods including electroporation, calcium phosphate transfection, micro-injection, or incorporation of the gene constructs into liposomes followed by transfection. The cells are then introduced into the patient for antibody expression *in vivo*.

The gene constructs are made by the cloning strategy as set forth above for construction of the diabodies and triabodies of the invention. The heavy and light chain genes can be placed in one plasmid construct either under separate promoter control or under one promoter in a dicistronic arrangement. The antibody gene fragments can also be placed under control of promoters that allow the turning on and off of the gene expression with appropriate exogenous factors such as steroids or metal ions.

These gene constructs can be prepared as plasmids for direct DNA delivery into host cells or tissues. With additional manipulations using techniques known in the field of genetic therapy, the gene constructs can also be coupled with a suitable viral particle, including a retrovirus, an adenovirus, or a parvovirus which allow gene delivery through viral infection. Any of these gene constructs can also be used to transfect cells suitable for antibody expression *ex vivo*. Following transfection, the cells are introduced into the subject where the antibody is expressed.

To test whether these gene constructs can direct the expression of the desired antibody or antibody fragments, suitable gene constructs or viral particles are first used to transfect or infect appropriate host cells. Culture supernatants of the transfected/infected cells are collected an appropriate period post transfection/transfection and tested for antibody expression in ELISA to detect the presence of the antibody and its ability to bind CD40 and CD86, or CD40, CD80 and CD86, if applicable. Further testing can include the measurement of the antibody affinity and the ability to compete with the parent antibodies for binding to the antigens.

To test whether the gene constructs or the cells transfected/infected as above can direct the antibody expression *in vivo*, plasmid gene constructs (or the transfected/infected cells) can be administered to BALB/c mice intramuscularly, either formulated with phosphate buffered saline or with suitable liposome preparation, or in the case of viral vectors, using proper infection protocols. The treated animals are analyzed for expression of the diabodies, triabodies or fusion proteins, as applicable, either with tissue section staining, or by expression thereof in blood.

Claims

1. A soluble molecule capable of binding to the human CD40 antigen and to the human CD86 antigen, said antigens being located on the surface of human lymphocytes.
2. A soluble binding molecule according to claim 1, which is an antibody containing an antigen-binding site of an antibody to CD40 and an antigen-binding site of an antibody to CD86.
3. An antibody molecule according to claim 2, which is a trispecific diabody capable of binding to CD40 and to both CD80 and CD86, in particular by containing the antigen-binding site of an antibody to CD40 and the antigen-binding site of an antibody which is cross-reactive with CD80 and CD86.
4. An antibody molecule according to claim 2, which is a bispecific diabody capable of binding to human CD40 and to human CD86, in particular by containing the antigen-binding site of an antibody to CD40 and the antigen-binding site of an antibody to CD86.
5. An antibody molecule according to claim 2, which is a trispecific triabody capable of binding to CD40, CD80 and CD86, in particular by containing the antigen-binding site of an antibody to CD40, the antigen-binding site of an antibody to CD80 and the antigen-binding site of an antibody to CD86.
6. A soluble binding molecule according to claim 1 or 3, which is capable of binding to CD86 by means of the extracellular domain of human CTLA-4.
7. An antibody according to claim 4 or 5, wherein the antibody to CD86 is the antibody Fun-1.
8. An antibody according to any one of claims 2 to 5 wherein the antibody to CD40 is an antagonistic antibody to CD40.
9. An antibody according to any one of claims 2-5, wherein the antibody to CD40 is a non-stimulatory antagonistic antibody to CD40.
10. A recombinant vector comprising the nucleotide sequences encoding the binding molecule fragments according to any one of claims 1-5 operably linked to regulating sequences capable of expressing the antibody molecule in a host cell.

11. A host cell stably transformed with the vector according to claim 10.
12. A method of producing a recombinant molecule capable of binding to the human CD40 antigen and to at least the human CD86 antigen, comprising culturing a host cell and isolating the binding molecule from the culture medium.
13. A pharmaceutical composition for induction of T cell tolerance, containing a therapeutically effective amount of the binding molecule according to any one of claims 1-5 and a pharmaceutically acceptable carrier.
14. A method for treating T cell mediated immune responses, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition according to claim 13.
15. A method for preventing allograft transplant rejection, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition according to claim 13.
16. A method for preventing xenotransplant rejection, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition according to claim 13.
17. A method for the induction of T cell tolerance, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition according to claim 13.
18. A method for the induction of allo-transplant or xeno-transplant tolerance, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition according to claim 13.
19. A method for preventing or treatment of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and psoriasis, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition according to claim 13.
20. A method for treating T cell mediated immune responses to gene therapy vectors or vehicles, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition according to claim 13.
21. A method for treating T cell mediated immune responses to therapeutic molecules, the

method comprising administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition according to claim 13.

22. Gene constructs encoding ligands capable of binding to CD40 and CD86, or to CD40, CD80 and CD86.
23. The gene constructs of claim 22 wherein the ligands encode triabodies or diabodies.
24. The constructs of claim 22 wherein the ligand capable of binding to CD86 is a CTLA4-Ig fusion protein.
25. The gene constructs of any of claims 22 to 24 wherein the gene constructs are incorporated in a plasmid or a viral vector.
26. A method of transfecting cells with the gene constructs of any of claims 22 to 24.
27. Cells transfected or infected with the gene constructs of any of claims 22 to 24.
28. The method of claim 25 wherein the transfection or infection is done *ex vivo* or *in vivo*.
29. The method of claim 27 wherein the transfection is done *ex vivo* by electroporation, calcium phosphate transfection, micro-injection or by incorporating the gene constructs into suitable liposomes.
30. The method of claim 27 wherein the infection is done *in vivo* or *ex vivo* by incorporating the gene constructs into a retrovirus, adenovirus or a parvovirus vector, or by incorporating the gene constructs, or the gene constructs with a viral vector, into a suitable liposome.

Abstract

The invention provides a ligand capable of binding to the human CD40 antigen and to the human CD86 antigen, and optionally to the CD80 antigen, said antigens being located on the surface of human lymphocytes, as well as vectors capable of producing the ligand and uses of the ligand in inducing T cell tolerance. Said ligand can be an antibody, which can be a trispecific diabody capable of binding to CD40 and to both CD80 and CD86, or a bispecific diabody capable of binding to human CD40 and to human CD86, or else a trispecific triabody capable of binding to CD40, CD80 and CD86.

SEQUENCE LISTING

<110> Mark de Boer
Marcel Theodorus

<120> Induction of T cell tolerance with
CD40/B7 antagonists

<130> 99-1

<150> 60/022,070

<151> 1996-07-23

<150> PCT/NL97/00438

<151> 1997-07-23

<160> 22

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 52

<212> DNA

<213> human

<400> 1

gcgcaggctt ggcccagccg gccatggccc aggtsmarct gcagsagtct gg

52

<210> 2

<211> 89

<212> DNA

<213> human

<400> 2

gtgagctoga tgtccgatcc gccaccgcca gagccacctc cgctgaacc gcctccacct
gaggagacgg tgaccgtggt cccttggcc

60

89

<210> 3

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> human

<400> 3

gacatcgagc tcacycagtc tcca

24

<210> 4

<211> 42

<212> DNA

<213> human

<400> 4

gcgcgcggcc gcccgtttka tttccagstt ggtgcctcca cc

42

<210> 5
 <211> 339
 <212> DNA
 <213> human

<400> 5
 caggtgcaac tctgtggagtc tggacctggc ctggtgaaac cctcacagag cctgtccatc 60
 acatgcactg tctctggggt ctcattatcc agatatagtg tatactgggt tcgccagcct 120
 ccaggaaagg gtctggagtg gctgggaatg atgtggggtg gtggatccac agactataat 180
 tcagctctca aatccagact gaccatcagc aaggacacct cgaagaacca ggtcttctta 240
 aaaatgaaca gtctgcgagc tgaggacaca gccatgtact actgtgtcag aaccgatggg 300
 gactactggg gtcaaggaaac caccgtcacc gtctctctca 339

<210> 6
 <211> 339
 <212> DNA
 <213> human

<400> 6
 gacctccagc tgacctcagtc tccactctcc ctgcctgtca gtcttggaga tcgagcctcc 60
 atctcttgca gatctagtc gagccttgta aacagtaatg gaaacaccta ttacattgg 120
 tacctgcaga agccaggcca gtctccaaag ctctgatct acaaagtttc caaccgattt 180
 tctggggctc cagacagggt cagtggcagt ggatcaggga cagatttcac actcaagatt 240
 agcagagtgg aggctgagga tgtgggagtt tattactgct ctcaaagtac acatgttccg 300
 tggacgttcg gtggaggcac caagctggaa atcaaacga 339

<210> 7
 <211> 723
 <212> DNA
 <213> human

<400> 7
 caggtgcagc tgcaggagtc tggacctggc ctggtgaaac cctcacagag cctgtccatc 60
 acatgcactg tctctggggt ctcattatcc agatatagtg tatactgggt tcgccagcct 120
 ccaggaaagg gtctggagtg gctgggaatg atgtggggtg gtggatccac agactataat 180
 tcagctctca aatccagact gaccatcagc aaggacacct cgaagaacca ggtcttctta 240
 aaaatgaaca gtctgcgagc tgaggacaca gccatgtact actgtgtcag aaccgatggg 300
 gactactggg gccaaaggac caccgtcacc gtctctcag gtggaggcgg ttcaggcggg 360
 ggtggctctg gcgggtggcg atcggacatc gagctcactc agtctccact ctccctgcct 420
 gtcagtcttg gagatcgagc ctccatctct tgcagatcta gtcagagcct tgtaaacagt 480
 aatggaaaca cctattttaca ttggtacctg cagaagccag gccagtctcc aaagctcctg 540
 atctacaaaag ttctcaaccg attttctggg gtcccagaca ggttcagtgg cagtggatca 600
 gggacagatt tcacactcaa gattagcaga gtggaggctg aggatgtggg agtttattac 660
 tgctctcaaa gtacacatgt tccgtggacg ttcggtggag gcaccaagct ggaaataaaa 720
 cgg 723

<210> 8
 <211> 375
 <212> DNA
 <213> human

<400> 8
 gaggtccaac tgcagcagtc tggacctgag ctggagaagg ctggcgcttc agtgaagata 60
 tcctgcaagg cttctgggta ctcattcact gactacaaca tgaactgggt gaagcagagc 120
 aatggaaaga gccttgagtg gattggaaat attgacctt actatgggtg tactagttac 180
 aatcagaagt tcaagggcaa ggccacattg actgtagaca aatcctccag cacagcctac 240
 atgcagctca acagcctgac atctgaagac tctgcagtct atttctgtgc aagatgggac 300

tataggtacg acgacgggag ggcttactat gttatggact tctgggggtca aggaacctca	360
gtcaccgtct cctca	375

<210> 9
 <211> 339
 <212> DNA
 <213> human

<400> 9	
gagctccaga tgcaccagtc tccatcatct ctggctgcgt ctgcaggaga aaaggctcact	60
atgagctgta agtccagtca aagtgtttta tacagttcaa atcagaagaa ctacttggcc	120
tgggtaccagc agaaaccagg gcagtctcct aaactgctga tctactgggc atccactagg	180
gaatctggtg tccctgatcg cttcacaggc agtggatctg ggacacattt tactctgacc	240
gtcagcagtg tgcaagctga agacctggca gtttattact gtcatcaata cctctactcg	300
tggacgttcg gtggaggcac caacctggaa atcaaacgg	339

<210> 10
 <211> 759
 <212> DNA
 <213> human

<400> 10	
cagggtccaac tgcagcagtc tggacctgag ctggagaagc ctggcgcttc agtgaagata	60
tcctgcaagg cttctggtta ctcatcact gactacaaca tgaactgggt gaagcagagc	120
aatggaaaga gccttgagtg gattggaaat attgatcctt actatggtgg tactagttac	180
aatcagaagt tcaagggcaa ggccacattg actgtagaca aatcctocag cacagcctac	240
atgcagctca acagcctgac atctgaagac tctgcagtct atttctgtgc aagatgggac	300
tataggtacg acgacgggag ggcttactat gttatggact tctggggcca agggaccacg	360
gtcaccgtct cctcaggtg aggcggttca ggcgagggtg gctctggcgg tggcggtatg	420
gacatcgagc tcacccagtc tccatcatct ctggctgcgt ctgcaggaga aaaggctcact	480
atgagctgta agtccagtca aagtgtttta tacagttcaa atcagaagaa ctacttggcc	540
tgggtaccagc agaaaccagg gcagtctcct aaactgctga tctactgggc atccactagg	600
gaatctggtg tccctgatcg cttcacaggc agtggatctg ggacacattt tactctgacc	660
gtcagcagtg tgcaagctga agacctggca gtttattact gtcatcaata cctctactcg	720
tggacgttcg gtggaggcac caacctggaa atcaaacgg	759

<210> 11
 <211> 35
 <212> DNA
 <213> human

<400> 11	
tctcacagtg cacaggtgca gctgcaggag tctgg	35

<210> 12
 <211> 51
 <212> DNA
 <213> human

<400> 12	
cgtgagaaca tatggcgcgc cttattaccg tttgatttcc aggttggtgc c	51

<210> 13
 <211> 764
 <212> DNA
 <213> human

<400> 13
 gtgaaaaaat tattattcgc aattccttta gttgttcctt tctatttctca cagtgcacag 60
 gtgcagctgc aggagtctgg acctggcctg gtgaaaccct cacagagcct gtccatcaca 120
 tgcactgtct ctgggttctc attatccaga tatagtgtat actgggttcg ccagcctcca 180
 ggaaagggtc tggagtggct gggaatgatg tgggggtggtg gatccacaga ctataattca 240
 gctctcaa at ccagactgac catcagcaag gacacctcga agaaccaggt cttcttaaaa 300
 atgaacagtc tgcgagctga ggacacagcc atgtactact gtgtcagaac cgatggggac 360
 tactggggcc aagggaccac ggtcaccgtc tctcaggtg gaggcgggtc agacattgag 420
 ctacccagtc ctccatcatc tctggctgcg tctgcaggag aaaagggtcac tatgagctgt 480
 aagtcagtc aaagtgtttt atacagttca aatcagaaga actacttggc ctggtaccag 540
 cagaaaccag ggcagtcctc taaactgctg atctactggg catccactag ggaatctggt 600
 gtccctgac gcttcacagg cagtggatct gggacacatt ttactctgac cgtcagcagt 660
 gtgcaagctg aagacctggc agttttattac tgtcatcaat acctctactc gtggacgttc 720
 ggtggaggca ccaacctgga aatcaaacgg taataaggcg cgcc 764

<210> 14
 <211> 30
 <212> DNA
 <213> human

<400> 14
 gcgcgaattc atggacatga ggggtccccgc 30

<210> 15
 <211> 27
 <212> DNA
 <213> human

<400> 15
 agatttgggc tcaactttct tgtccac 27

<210> 16
 <211> 27
 <212> DNA
 <213> human

<400> 16
 gtggacaaga aagttgagcc caaatct 27

<210> 17
 <211> 82
 <212> DNA
 <213> human

<400> 17
 gcgcgaattc ttaagcggcc gcagatccgc cgccaccoga cccacctccg cccgagccac 60
 cgccaccttt acccgagac ag 82

<210> 18
 <211> 31
 <212> DNA
 <213> human

<400> 18
 gcgcgcggcc gcaatgcacg tggcccagct t 31

<210> 19

<211> 36
 <212> DNA
 <213> human

<400> 19
 gcgcgcggcc gcctagtcag aatctgggca cggttc 36

<210> 20
 <211> 31
 <212> DNA
 <213> human

<400> 20
 gcggcggtac catggacatg aggggtccccg c 31


<210> 21
 <211> 33
 <212> DNA
 <213> human

<400> 21
 gcgcggatcc ctaacactct cccctgttga agc 33

<210> 22
 <211> 879
 <212> DNA
 <213> human


<400> 22
 atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc 60
 atggcccagg tccaactgca gcagtctgga cctgagctgg agaagcctgg cgcttcagtg 120
 aagatatacct gcaaggcttc tggttactca ttcactgact acaacatgaa ctgggtgaag 180
 cagagcaatg gaaagagcct tgagtggatt ggaaatattg atccttacta tgggtggtact 240
 agttacaatc agaagttcaa gggcaaggcc acattgactg tagacaaatc ctccagcaca 300
 gcctacatgc agctcaacag cctgacatct gaagactctg cagtctatct ctgtgcaaga 360
 tgggactata ggtacgacga cgggagggct tactatgtta tggacttctg gggccaaggg 420
 accacgggtca ccgtctcctc aggcgggtggc ggatcggaca ttgagctcac tcagtctcca 480
 ctctccctgc ctgtcagttc tggagatcga gcctccatct cttgcagatc tagtcagagc 540
 cttgtaaaca gtaatggaaa cacctattta cattggtacc tgcagaagcc aggccagtct 600
 ccaaagctcc tgatctacaa agtttccaac cgattttctg ggggtcccaga caggttcagt 660
 ggcagtggtat cagggacaga tttcacactc aagattagca gagtggaggc tgaggatgtg 720
 ggagtttatt actgctctca aagtacacat gttccgtgga cgttcggtgg aggcaccaag 780
 ctggaaataa aacgggcggc cgcagaacaa aaactcatct cagaagagga tctgaatggg 840
 gccgcacatc accatcatca ccattaataa gaatccbct 879

Figure 1



2/7

Figure 2



SUBSTITUTE SHEET (RULE 26)

3/7

Figure 3





Figure 4



SUBSTITUTE SHEET (RULE 26)

5/7

Figure 5






Figure 6

Conditions during primary MLR



7/7

Figure 7



SUBSTITUTE SHEET (RULE 26)

COMBINED DECLARATION AND POWER OF ATTORNEY

Attorney's Docket 99-1

As a below named inventor, I hereby declare that:

This declaration is for an original application.

My residence, post office address and citizenship are as stated below next to my name. I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"Induction of T Cell Tolerance with CD40/B7 Antagonists"

the specification of which is filed herewith.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims.

I acknowledge the duty to disclose information which I know to be material to the patentability of this application as defined in Title 37, Code of Federal Regulations § 1.56.

As a named inventor, I hereby appoint the following attorney to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Eric P. Mirabel
Reg. No. 31,211

Send correspondence and direct telephone calls to:

Eric Mirabel
Tanox, Inc.
10301 Stella Link #110
Houston, TX 77025-5497
(713) 664-2288

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title

35, United States Code, Section 112, I acknowledge the duty to disclose to the Office information which I know to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

US Provisional Patent Application No. 60/022,070, filed on 7/23/96.

PCT International Application Serial No. PCT/NL97/00438, filed on 7/23/97.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of **first inventor**: Mark de Boer

Inventor's signature: _____

Date: _____ Country of Citizenship: The Netherlands


Residence and Post Office Address: Naarderweg 20, 126 BT Blaricum, The Netherlands

Full name of **second inventor**: Marcel Theodorus

Inventor's signature: _____

Date: _____ Country of Citizenship: The Netherlands

Residence and Post Office Address: Jan Persijnlaan 134, 1141 WN Monnickendam, The Netherlands

[illegible][illegible][illegible][illegible][illegible]